LV-10

LV-10 is a novel cell therapy consisting of engineered Type 1 regulatory T (Tr1) cells. These cells are generated by lentiviral transduction of interleukin-10 (IL-10) into peripheral CD4+ T cells. LV-10 cells are designed to provide a graft-versus-leukemia (GvL) effect against chemotherapy-resistant myeloid leukemias, including pediatric acute myeloid leukemia (pAML), while preventing graft-versus-host disease (GvHD). The cells mediate direct lysis of malignant myeloid cells via perforin and granzyme B, and their killing is facilitated by target cell expression of HLA class I. Resistance to LV-10 killing in pAML can be mediated by the upregulation of CD200 on target cells, which binds to the inhibitory receptor CD200R1 on LV-10 cells, impairing their cytotoxic function. The therapy is being developed for use in high-risk pAML patients, potentially alongside allogeneic hematopoietic stem cell transplantation (allo-HSCT) or as a treatment for minimal residual disease.